SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- LG and NVIDIA are expanding their strategic collaboration across industries, Physical AI, AI Infra and mobility...
Most surveyed technology leaders are accountable for systems they don't fully controlOnly 11% of respondents say they're completely prepared for the scale of AI...
$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7,...
Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6
ZURICH, June 07, 2026 (GLOBE NEWSWIRE) -- The cryptocurrency market is witnessing a massive convergence of artificial intelligence and digital culture. Investors are shifting capital toward functional crypto ecosystems. Memecoins have evolved far beyond basic internet jokes.
Pinellas Gulf Beach vacation rental and STR investment specialist places in the top 0.3% of residential real estate professionals in Florida, based on independently verified 2025 sales data
Pinellas Gulf Beach vacation rental and STR investment specialist places in the top 0.3% of residential real estate professionals in Florida, based on independently verified 2025 sales data
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978
All figures presented herein are in Canadian dollars, unless indicated otherwise.MONTREAL, June 5, 2026 /CNW/ - Birks Group Inc. ("Birks Group" or the "Company")...
NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Centurion Acquisition Corp., a Cayman Islands exempted company, (“Centurion” or the “Company”) (Nasdaq: ALF) today announced that it intends to postpone its previously announced Extraordinary General Meeting of shareholders (the “Meeting”) from June 9, 2026, at 11:00 a.m. Eastern Time, to June 12, 2026 at 11:00 a.m. Eastern Time to allow Centurion additional time to engage with shareholders.